Top Story

Timing of colonoscopy influences polyp detection rate

April 17, 2015

Colonoscopies performed in the morning are associated with a significantly higher rate of polyp detection, according to data presented at the Society of American Gastrointestinal and Endoscopic Surgeons 2015 Annual Meeting.

In order to evaluate the effect of timing variables on colonoscopy polyp detection rate, investigators analyzed a prospective colonoscopy database to compare polyp detection rates for 585 elective outpatient completed colonoscopies with adequate bowel preparation performed during a 4-hour morning shift (52.3%) vs. a 4-hour afternoon shift (47.7%) during a span of 1 year. Cancer surveillance colonoscopies were not included.

iPSC model aims to increase understanding of liver disease In the Journals

iPSC model aims to increase understanding of liver disease

April 17, 2015
Researchers from Boston University and Boston Medical Center have developed a patient-derived induced pluripotent stem cell model that could be used to better understand…
Meeting News Coverage

Single-incision cholecystectomy more stressful, physically demanding to surgeon

April 17, 2015
Compared with 4-port laparoscopic cholecystectomy, single-incision laparoscopic cholecystectomy may be more stressful and physically demanding to surgeons, which could…
The Big Picture

Staying Current on HCV: A Summary of Recent Updates to the Guidelines

HCV Next, April 2015
Sujit V. Janardhan, MD, PhD; Nancy S. Reau, MD
The rapid evolution of highly effective, curative therapies for hepatitis C virus infection, establishment of new HCV screening practice guidelines, and rising rates of…
Trend Watch

FDA Warns of Cardiac Reactions with Sofosbuvir Drug Combinations

HCV Next, April 2015
The FDA has approved changes to the warnings and precautions labels for Harvoni and Sovaldi, indicating that amiodarone should not be used while taking the combination…
More News Headlines »
CME
cover

HCV Council 2014 Recap Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape

This activity is supported by an educational grant from AbbVie Inc., Gilead Sciences, Inc., and Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Meeting News Coverage Video
thumbnail for video 4131516814001

'The time has come' for individualized treatment for obese, overweight patients

March 24, 2015
SAN FRANCISCO — Michael Camilleri, MD, AGAF, from the Mayo Clinic in Rochester, Minn., discusses his presentation…
More »
CME
Assessing Real-world Outcomes with New HCV Regimens in 2014: HCV-TARGET Registry Findings

Assessing Real-world Outcomes with New HCV Regimens in 2014: HCV-TARGET Registry Findings

We gratefully acknowledge the following company for their educational grant in support of this educational activity. Janssen Therapeutics, Division of Janssen Products, LP.

The field of HCV treatment is rapidly evolving, with 2 new direct-acting antiviral agents (DAA) approved at the end of…
More »
morganatic-roan